at Benzinga.com (Jan 13, 2015)
Rigel Pharmaceuticals (RIGL +4.9%) kicks up a gain after Citigroup upgrades shares to a Buy rating from Neutral. SA author Stephen Simpson notes that if the firm strikes some success with studies of drugs in its pipeline it may make a juicy acquisition candidate for AstraZeneca.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Dec 17, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Jun 5, 2013)
at CNBC.com (Jun 4, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs